Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer
September 06, 2022 07:00 ET
|
Landos Biopharma, Inc.
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases,...
Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update
August 11, 2022 08:30 ET
|
Landos Biopharma, Inc.
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early...
Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial
August 03, 2022 08:00 ET
|
Landos Biopharma, Inc.
NX-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-Daily Doses Results Indicate Promising Early Signals Regarding the Efficacy of NX-13 Phase 2 Proof of Concept...
Landos Names Gregory Oakes President and Chief Executive Officer
June 21, 2022 08:00 ET
|
Landos Biopharma, Inc.
Seasoned Pharmaceutical Executive Brings 25+ Years of Experience With a Focus on Successful Commercialization Company Remains On Track to Complete Review of Clinical Development Plans Later This...
Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update
May 12, 2022 16:05 ET
|
Landos Biopharma, Inc.
On Track to Complete Review of Clinical Development Plans by Mid-2022 Top-Line Results for NX-13 Phase 1b and LABP-104 Phase 1 Trials Remain On Track for Mid-2022 Plans to Announce Timing of Phase...
Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
March 24, 2022 16:45 ET
|
Landos Biopharma, Inc.
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of...
Landos Biopharma Appoints Roger Adsett to its Board of Directors
March 10, 2022 08:00 ET
|
Landos Biopharma, Inc.
BLACKSBURG, Va., March 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune...
Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021 07:30 ET
|
Landos Biopharma, Inc.
Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate...
Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis
November 02, 2021 08:28 ET
|
Landos Biopharma, Inc.
Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos’ seventh IND cleared overall and the second IND cleared for LABP-104, a potentially first-in-class...
Landos Biopharma Announces First Subject Dosed in a Phase 1 Study of LABP-104 for Systemic Lupus Erythematosus
October 28, 2021 07:00 ET
|
Landos Biopharma, Inc.
Topline results are expected in the first half of 2022 A whole blood LABP-104 precision medicine signature will be assessed during the trial BLACKSBURG, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) --...